The risk of infections with epcoritamab plus R2 appeared to be level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.
Bradley D. Hunter, MD
Advertisement
Articles by Bradley D. Hunter, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Which Lung Cancer Presentations Will Move the Needle at WCLC 2026?
2
Neoadjuvant Atezolizumab Does Not Significantly Improve EFS in Early TNBC
3
Novel Myelofibrosis Drug is “Versatile” for Managing Anemia
4
Early Camizestrant Is Favored Upon ESR1 Mutation Emergence in Breast Cancer
5